Price to Sales (P/S)
since 2005
Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Illumina Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenue1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2017 | = | ÷ | = | ÷ | |||||||
| Mar 2, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Illumina Inc. Annual Report.
- Share Price
- The share price exhibits significant growth over the observed period. Beginning at $12.79 in 2006, it showed a steady upward trajectory with some fluctuations, notably increasing to $69.40 in 2011, before experiencing a decline to $48.73 by 2013. Subsequently, a robust surge occurred, reaching a peak of $494.24 in 2021. This overall trend indicates strong market confidence and substantial value appreciation during these years.
- Sales per Share
- Sales per share consistently increased throughout the period, starting from $0.89 in 2006 to a peak of $24.10 in 2020. There was a slight decrease to $22.20 in 2021, which interrupts the otherwise upward growth pattern. The sustained increase over most years suggests steady revenue growth on a per-share basis, reflecting improving operational performance or increased sales volume.
- Price-to-Sales (P/S) Ratio
- The P/S ratio showed considerable volatility during the period. Initially, it was relatively high at 14.36 in 2006, then fluctuated downwards to a low of 5.26 in 2013. From 2013 onwards, it generally increased again, reaching 22.26 in 2021, the highest in the period. The variation in this ratio highlights changes in market valuation relative to sales, with the sharp rise in 2021 suggesting that the market may have assigned a premium valuation relative to the company's revenue at that time.
Comparison to Competitors
Illumina Inc., P/S, long-term trends, comparison to competitors
| Illumina Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2021 | |||||||||||||
| Feb 11, 2020 | |||||||||||||
| Feb 12, 2019 | |||||||||||||
| Feb 13, 2018 | |||||||||||||
| Feb 14, 2017 | |||||||||||||
| Mar 2, 2016 | |||||||||||||
| Feb 18, 2015 | |||||||||||||
| Feb 18, 2014 | |||||||||||||
| Feb 15, 2013 | |||||||||||||
| Feb 24, 2012 | |||||||||||||
| Feb 28, 2011 | |||||||||||||
| Feb 26, 2010 | |||||||||||||
| Feb 26, 2009 | |||||||||||||
| Feb 26, 2008 | |||||||||||||
| Feb 28, 2007 | |||||||||||||
| Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Illumina Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Illumina Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 17, 2021 | ||
| Feb 11, 2020 | ||
| Feb 12, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Mar 2, 2016 | ||
| Feb 18, 2015 | ||
| Feb 18, 2014 | ||
| Feb 15, 2013 | ||
| Feb 24, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 26, 2009 | ||
| Feb 26, 2008 | ||
| Feb 28, 2007 | ||
| Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).
Comparison to Industry (Health Care)
Illumina Inc., P/S, long-term trends, comparison to industry (health care)
| Illumina Inc. | Health Care | |
|---|---|---|
| Feb 17, 2021 | ||
| Feb 11, 2020 | ||
| Feb 12, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Mar 2, 2016 | ||
| Feb 18, 2015 | ||
| Feb 18, 2014 | ||
| Feb 15, 2013 | ||
| Feb 24, 2012 | ||
| Feb 28, 2011 | ||
| Feb 26, 2010 | ||
| Feb 26, 2009 | ||
| Feb 26, 2008 | ||
| Feb 28, 2007 | ||
| Mar 6, 2006 |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).